npg

# p53 isoform 113p53/ 133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage

Lu Gong<sup>1</sup>, Hongjian Gong<sup>1</sup>, Xiao Pan<sup>1</sup>, Changqing Chang<sup>3</sup>, Zhao Ou<sup>1</sup>, Shengfan Ye<sup>1</sup>, Le Yin<sup>1</sup>, Lina Yang<sup>1</sup>, Ting Tao<sup>2</sup>, Zhenhai Zhang<sup>4</sup>, Cong Liu<sup>5</sup>, David P Lane<sup>6</sup>, Jinrong Peng<sup>2</sup>, Jun Chen<sup>1</sup>

of environmental factors, such as ionizing radiation and various chemical agents (e.g., methyl methanesulfonate and bleomycin), can cause DNA DSBs [1]. To survive in such DNA damage stress conditions, it is very important for an organism to decide which cells are non-repairable and thus can be induced to die and which cells are repairable and thus can survive after DNA damage repair. However, how these decisions are made in response to DNA DSBs remains unexplored.

A central part of the DNA damage response is the activation of the tumor repressor gene, p53. Upon activation, p53 upregulates or represses the expression of a large number of downstream genes. The promoters of genes activated by p53 usually contain a consensus sequence of two pairs (half-sites) of pentamers arranged head-to-head, 5'-RRRC(A/T)(A/T)GYYY-3' (R: purine, Y: pyrimidine), separated by 0-38 nucleotides. The promoters of genes repressed by p53 usually contain a consensus sequence of two pairs of pentamers arranged end-to-head, 5'-RRRC(A/T)(N)RRRC(A/T)-3' or 5'-(A/ T)GYYY(N)(A/T)GYYY-3' (N: purine or pyrimidine), separated by 0-13 nucleotides [5, 6]. The expression of p53 downstream genes triggers cell cycle arrest, DNA damage repair, apoptosis and/or senescence to ensure genome stability [7, 8]. Intriguingly, p53 protein appears to promote only some DNA damage repair pathways, such as base excision repair, mismatch repair and nucleotide excision repair [9-11], but inhibit DNA DSB repair pathways, including the HR, NHEJ and SSA pathways [12-14]. It has been demonstrated that p53 exerts a direct effect on DNA DSB repair, as mutations in p53 that impair or even abolish its transcriptional activity and cell cycle regulatory capacity do not significantly affect its inhibition of HR [15-17]. Further experiments have shown that the p53 protein is able to interact with repair proteins to prevent repair complex formation, such as RAD51 (a recombinase for HR) and replication protein A (RPA; a single-strand DNA-interacting protein required for stabilizing processed DNA ends) [16, 18, 19]. In contrast, there is also evidence that p53 transcriptionally inhibits the expression of repair genes, such as RAD51 [20]. Recent studies have shown that the p53 protein relies on dynamic changes in its levels to control cell fate in response to DNA DSB stress, such as -irradiation, which is quite different from a single p53 pulse induced by UV irradiation [21, 22]. Therefore, although full-length p53 inhibits DNA DSB repair, it is not clear how the p53 signal pathway regulates DNA DSB repair in response to DNA DSB stress.

The zebrafish protein 113p53 and its human counterpart 133p53 are N-terminally truncated forms of p53 with deletion of both the MDM2-interacting motif and the transactivation domain, together with partial deletion of the DNA-binding domain [23-25]. *113p53/ 133p53* is a p53 target gene, which is transcribed by an alternative *p53* promoter in intron 4. It is strongly induced by DNA damage stress to antagonize p53-mediated apoptosis [26-28]. Our previous studies showed that 113p53 does not act on p53 in a dominant-negative manner, but rather interferes with p53 function by differentially modulating p53 target gene expression to protect cells from apoptosis [26]. 133p53 also represses cell replication senescence [29] and promotes angiogenesis and tumor progression [30]. However, knowledge of its function in DNA DSB repair is lacking.


In this study, we demonstrate that 113p53/ 133p53 is strongly accumulated at the later stage in response to DNA DSB signals, such as -irradiation, to promote all three DNA DSB repair pathways in both zebrafsh and human cells. We also demonstrate that 113p53/ 133p53 regulates DNA DSB repair by transcriptionally upregulating the expression of *RAD51*, *LIG4* and *RAD52*, independent of full-length p53. Our fndings provide an important clue to unravel the perplex of p53 in the DSB repair.

## Results

# Zebrafsh 113p53 expression was strongly induced by -irradiation, but not UV irradiation and heat shock treatment

We showed previously that 113p53 expression is induced by -irradiation [26]. In the current study, we examined the expression of 113p53 in zebrafsh embryos after UV irradiation and heat shock treatment. We found that although upregulation of full-length p53 expression reached a similar level upon different treatments, the expression of 113p53 was only induced by 16 gray of -irradiation and was not, or only weakly, induced by other treatments (Figure 1A and Supplementary information, Figure S1A). This induction appears to be a specifc outcome of -irradiation treatment, because there was no, or only a low-level, induction of 113p53 expression even when embryos were exposed to harsher UV or higher temperature conditions that caused most embryos to die at 32 hours post treatment (hpt). In contrast, almost 100% of embryos treated with 16 gray of -irradiation survived at 32 hpt (Supplementary information, Figure S1B). Upon exposure to -irradiation, p53 levels peaked as early as 4 hours post irradiation (hpi), whereas 113p53 levels peaked later, at 24 hpi (Figure 1B). As the main difference in the damage induced by the different treatments was that only -irradiation led to genome-wide DNA DSBs, we speculated whether the high





level of 113p53 induced by -irradiation might play a role in DNA DSB repair.

## Zebrafsh 113p53 promotes DNA DSB repair

To test our hypothesis, we used three Egfp-repairing-aided visual-plus-quantitative analysis reporter systems to measure HR, NHEJ and SSA repairs [31] (Supplementary information, Figure S2). The corresponding plasmids were linearized with I-SceI, and then co-injected with p53 morpholino (p53-MO, which targets the ATG of full-length p53 mRNA to block its translation), 113p53 morpholino (113p53-MO, which specifcally targets the 5'-UTR of 113p53 mRNA) [26] or a p53-MO-plus- 113p53 mRNA mix into zebrafsh wild-type (WT) embryos. The linearized plasmid DNA was also co-injected into  $p53^{M214K}$  mutant embryos ( $p53^{M214K}$  carries an M214-to-K214 substitution in the DNA-binding domain [32]) with p53 mRNA, 113p53 mRNA or a p53plus- 113p53 mRNA mix (Supplementary information, Figure S3). Protein analysis showed that injection of linearized plasmid alone activated the p53 pathway, which further induced *113p53* expression in WT embryos (Supplementary information, Figure S4). We confrmed DSB repair in each treatment at 8 hours post fertilization (hpf), by either EGFP fluorescence intensity measurement or quantitative real-time PCR (qPCR) analysis of the repaired Egfp DNA fragments. Our results showed that zebrafish p53, like human p53, inhibited all three DNA DSB repair pathways at 8 hpf (Figure 1C, lanes 3 vs 1 and 7 vs 5, and Supplementary information, Figure S5). Knockdown of 113p53 signifcantly enhanced the inhibitory effect of the endogenous p53 on DSB repair (Figure 1C, lanes 2 vs 1, and Supplementary information, Figure S5). In contrast, the overexpression of 113p53 promoted all three DSB repair pathways in p53 mutant embryos (Figure 1C, lanes 6 vs 5, and Supplementary information, Figure S5). To investigate whether p53<sup>M214K</sup> 113p53<sup>M214K</sup> mutant proteins have a gain-of-funcand tion effect on DNA DSB repairs, we co-injected the linearized repair plasmids with either p53-MO or 113p53-MO into  $p53^{M214K}$  mutant embryos (Supplementary information, Figure S6). The qPCR analysis of the repaired Egfp DNA fragments showed that knockdown of either p53<sup>M214K</sup> or 113p53<sup>M214K</sup> mutant protein had little effects on HR, NHEJ and SSA repairs, suggesting that both mutant proteins do not have a gain-of-function effect on DNA DSB repairs.

We next investigated the influence of 113p53 on DNA DSB repair of genomic DNA using a comet assay (single cell gel electrophoresis) by analyzing the genomic DNA damage induced by -irradiation in zebrafish embryos (Supplementary information, Figure S7). WT

and  $p53^{M214K}$  mutant embryos were injected with either the standard control morpholino (Std-MO, against human -globin) or 113p53-MO. The injected WT and  $p53^{M214K}$  mutant embryos were treated with 16 gray of -irradiation (Figure 1D). A TUNEL assay showed that apoptosis decreased to the basal level after 24 hpi (Supplementary information, Figure S8). We thus used 28hpi and 36-hpi irradiated embryos to detect the levels of DNA DSB, minimizing the interference of apoptosis in the assay. Our results showed that the extent of DNA damage in WT embryos with 113p53 knockdown was ~2-fold of that in the irradiated control embryos at either 28 hpi or 36 hpi (Figure 1E). Very interestingly, the extent of DNA damage dropped faster in WT embryos (from 4.76 at 28 hpi to 0.37 at 36 hpi, 12.86-fold) than in the  $p53^{M214K}$  mutants (from 2.72 at 28 hpi to 0.59 at 36 hpi,  $\sim$ 4.6-fold), which correlated well with the presence of

113p53 accumulation in WT and its absence in  $p53^{M214K}$ embryos induced by -irradiation (Figure 1D and 1E). Notably, the extent of DNA damage in the irradiated WT embryos (4.76) was significantly higher than that in the irradiated p53<sup>M214K</sup> embryos (2.72) at 28 hpi. In contrast, at 36 hpi, the extent of DNA damage was signifcantly lower in the irradiated WT (0.37) than in the irradiated  $p53^{M214K}$  embryos (0.59). One possible explanation for this observation is that full-length p53 is induced to a high level at the early stage (Figure 1B) in WT embryos after irradiation, which could guide the cells with severe DNA damage towards apoptosis while repressing DNA DSB repair in the surviving cells. On the other hand, due to the lack of bioactive p53, the DNA-damaged cells in the  $p53^{M214K}$  mutant were still able to undergo the DNA DSB repair. Hence, we observed that the extent of DNA damage was higher in WT than that in  $p53^{M214K}$  at 28 hpi. At 36 hpi, the expression of 113p53 in WT embryos accumulated to a high level, which in turn blocked apoptosis and promoted DNA DSB repair in the surviving cells. This resulted in a drastic drop in the extent of DNA damage in these WT cells. However, in the irradiated  $p53^{M214K}$ embryos, although the DNA-damaged cells were able to undergo DNA DSB repair, the repair effciency was low due to the absence of 113p53 expression (Figure 1D). Furthermore, the irradiated  $p53^{M214K}$  embryos contained a large number of non-repairable cells with severe DNA damage, which escaped apoptosis in the absence of the bioactive p53. As a result, cells in  $p53^{M214K}$  embryos exhibited signifcantly higher levels of DNA damage than those in WT embryos at 36 hpi. These results demonstrate the importance of the coordination of p53 and

113p53 functions at the organismal level to minimize DNA damage upon DNA DSB stress.

# Generation of zebrafsh 113p53<sup>M/M</sup> mutant

To study the biological significance of 113p53 in DNA DSB repair, we generated a zebrafsh  $113p53^{Mu-tation/mutation (M/M)}$  knockout mutant. As the coding sequence of 113p53 is completely overlapped with the full-length p53, we chose to knock out 113p53 by targeting its promoter. One of our previous studies showed that the 113p53 promoter is located in the fourth intron of the full-length p53 gene and contains three putative p53 response elements (REs) [26] (Figure 2A). A subsequent study showed that the third p53 RE is required for

113p53 expression (unpublished data). Therefore, we generated a 113p53 mutant by targeting the third p53 RE in its promoter with the transcription activator-like effector nuclease (TALEN) technique. One mutant was obtained with an 11-bp deletion, which includes an 8-bp sequence within the third p53 RE (Figure 2A). Western blot showed that the induction of 113p53 expression was almost completely blocked, whereas the activation of full-length p53 was unaffected in the 113p53<sup>M/M</sup> mutants in response to -irradiation (Figure 2B).

# Zebrafish $113p53^{M/M}$ mutant is more sensitive to -irradiation due to loss of functions in anti-apoptosis and promoting DNA DSB repair

The 113p53<sup>M/M</sup> mutant fsh grows to adulthood normally in standard growth conditions. To test whether three DNA DSB repair pathways are affected in the mutant, the I-SceI-linearized HR, NHEJ or SSA plasmid was injected into WT and 113p53<sup>M/M</sup> embryos, and was co-injected with 113p53 mRNA into 113p53<sup>M/M</sup> embryos. Results showed that the effciency of the three DNA DSB repair pathways was significantly decreased in 113p53<sup>M/M</sup> embryos (Supplementary information, Figure S9), which is similar to that observed in the 113p53-MO-injected embryos (Figure 1C). The effciency of all three repair pathways was restored by 113p53 mRNA co-injection (Supplementary information, Figure S9), demonstrating that the decrease of DNA DSB repair effciency in 113p53<sup>M/M</sup> embryos was due to the absence of 113p53.

We then treated WT and  $113p53^{M/M}$  embryos with -irradiation. Assessment of embryo viability revealed that the  $113p53^{M/M}$  embryos (all of which died at 5 dpi) were much more susceptible to -irradiation than WT embryos (~30% of which was viable at 5 dpi; Figure 2C and 2D). Two main functions of 113p53 have been demonstrated, i.e., to antagonize the pro-apoptotic function of p53 and to promote DNA DSB repair. To determine the contribution of 113p53's DSB repair function to the high mortality rate in the mutant embryos in response to -irradiation, we blocked cell apoptosis by injecting *bcl2L* (anti-apoptotic protein) [26] mRNA into

113p53 (Figure 2B). Similar to the results in embryos injected with 113p53-MO [26], more apoptotic cells were observed in  $113p53^{M/M}$  embryos than in WT embryos upon -irradiation (Figure 2E). However, irradiation-induced apoptosis was almost completely inhibited by *bcl2L* mRNA injection in both WT and  $113p53^{M/M}$ embryos (Figure 2E). The viability of irradiated mutant embryos injected with bcl2L mRNA (~20% at 5 dpi) was significantly lower than that of WT embryos (~50%) with the same treatment, and even lower than that of irradiated WT embryos (~30%) without bcl2L mRNA injection (albeit with abundant apoptotic cells; Figure 2C and 2D). Comet assay results showed that bcl2L mRNA injection slightly increased the extent of DNA damage in both irradiated WT and  $113p53^{M/M}$  embryos at a similar scale. This increase occurred possibly because Bcl2L overexpression prevented cells with severe DNA damage from apoptosis in both irradiated WT and  $113p53^{M/M}$  embryos (Figure 2F). Converselv. 113p53 mRNA injection restored the viability of irradiated mutant embryos to the WT level upon -irradiation (Supplementary information, Figure S10). Taken together, these results suggest that loss of both functions of 113p53 (i.e., anti-apoptosis and promotion of DNA DSB repair) renders 113p53<sup>M/M</sup> embryos more sensitive to -irradiation.


## The promotion of DNA DSB repair is conserved in human 133p53

We treated human QSG-7701 cells (a non-cancerous liver epithelial cell line containing WT *p53*) with -irradiation, UV irradiation and heat shock, and analyzed the function of the human ortholog, 133p53, in DNA DSB repair. Both 133p53 transcript and protein were strongly induced by -irradiation only (Figure 3A; Supplementary information, Figure S11A-S11C). We then transfected the H1299 cells (which lack the endogenous *p53* gene) with each of the three visual-plus-quantitative assay constructs, along with *133p53*, *p53* or *p53*-plus-*133p53* mRNA (Supplementary information, Figure S12). Both qPCR analysis of the repaired *Egfp* DNA fragments and fluorescence-activated cell sorting (FACS) analysis of EGFP-positive cells revealed that, apart from neutralizing the DSB repair inhibitory effect of full-length p53,

133p53 also almost doubled the efficiency of all the three DNA DSB repair pathways in a p53-independent manner, compared to their corresponding controls (Figure 3B and Supplementary information, Figure S13). To study the function of endogenous 133p53 in DNA DSB repair, we co-transfected each of the three repair assay constructs with either a non-specifc siRNA control

Figure 2 MM (A) MM (B) bc/2L (C D) MM bc/2L (C) (D) (E)

(**F**)



(siNS) or two 133p53 siRNAs, siRNA1 (133p53i-1) or siRNA2 (133p53i-2; both targeting 5'-UTR of 133p53 located in the intron 4 of full-length p53) [29] into QSG-7701 cells (Supplementary information, Figure S14A). The qPCR analysis showed that the knockdown of 133p53 signifcantly decreased the effciencies of the three DNA DSB repair pathways (Supplementary information, Figure S14B). The positive role of 133p53 in DNA DSB repair was also observed in U2OS cells (Figure 3C), which harbor WT p53 and stably express HR-GFP [33].

It has been reported that human p53 inhibits RAD51 foci formation in response to DNA damage [34, 35]. We used QSG-7701 cells to study the function of 133p53 in the formation of the DNA DSB repair foci of phosphorylated H2AX (H2AX; which is one of the early

DNA DSB repair markers) and RAD51 upon -irradiation. QSG-7701 cells were transfected with either a non-specifc siRNA control (siNS), a *p53* siRNA (p53i; targeting exon 4 of full-length p53) [27], or two *133p53* siRNAs,

133p53i-1 and 133p53i-2, and treated with 10 gray of -irradiation (Figure 4A). Our results confrmed that p53 has a negative infuence on RAD51 foci formation (Figure 4B and 4C; Supplementary information, Figure S15). In contrast, overexpression of 133p53 significantly increased RAD51 foci formation at 12 hpi upon -irradiation, whereas knockdown of endogenous 133p53 signif cantly decreased foci formation under the same conditions (Figure 4B, 4C and Supplementary information, Figure S15). Our results also showed that the formation of H2AX foci was not signif cantly affected by 133p53 or p53 overexpression, suggesting that 133p53 and p53

may not have a significant effect on the early steps of DNA DSB repair (Figure 4B, 4C and Supplementary information, Figure S15).

FACS analysis revealed, as expected, that the number of apoptotic cells (sub-G0 summit) was decreased by p53 knockdown from 8 to 24 hpi and was increased by

133p53 knockdown from 4 to 24 hpi (Supplementary information, Figure S16) [23, 26]. However, apoptosis decreased to the basal level by 36 hpi in all cases (Supplementary information, Figure S16). Therefore, we performed the comet assay at 48 hpi to test whether the decrease in the number of RAD51 foci upon 133p53 knockdown was accompanied by an increase in DNA damage. Comet assay results showed ~1.5-fold greater damage in cells transfected with the 133p53 siRNAs than in the irradiated control cells (Figure 4D). These results demonstrate that 133p53 plays a positive role in genomic DNA DSB repair upon -irradiation. However, the extent of DNA damage in irradiated control cells (1.0) was only slightly lower than that in irradiated p53-knockdown cells (1.1) at 48 hpi (Figure 4D), which differed from the comet assay results obtained from irradiated zebrafish WT and  $p53^{M214K}$  embryos at 36 hpi (Figure 1E). One likely explanation is that in embryos, apoptotic cells are cleared away by other cells in vivo, while in cell culture conditions, there is no such system to remove the apoptotic cells, which may interfere with the comet assay carried out in cultured cells.

## Knockdown of 133p53 in human cells inhibits cell proliferation through arresting cell cycle at the G2 phase and promoting cell senescence upon -irradiation

To study the consequence of increased DNA damage at the cellular level, we transfected QSG-7701 cells with siNS, 133p53i-1, or 133p53i-2 and treated them with 10 gray of -irradiation. As described above, apoptosis decreased to the basal level at 36 hpi (Supplementary information, Figure S14). We washed away apoptotic cells at 2 dpi and replaced with a new culture medium to allow the remaining cells to grow under normal conditions. At 5 dpi, total cell number and colony size (which showed flattened cell morphology) were observably decreased by the treatment of -irradiation, compared to those of unirradiated controls (Figure 5A). Interestingly, after -irradiation fewer cell numbers and a smaller colony size were observed in cells transfected with 133p53 siRNA compared with the siNS-transfected control (Figure 5A), which correlates well with the extent of DNA damage observed (Figure 4D). FACS analysis of cells at 5 dpi showed that the proportion of cells at the G2 phase increased slightly, from 14.1% to 19.6%, in siNS-transfected cells, but almost doubled from 16.8%

to 35.5% in 133p53i-1- and from 17.6% to 34.6% in 133p53i-2-transfected cells (Figure 5B). In contrast, there was little difference in the proportion of cells at the S phase between the irradiated cells and untreated controls (Figure 5B). These results suggest that a high level of DNA damage results in cell cycle arrest at the G2 phase.


Next, cell senescence analysis was performed with senescence-associated -galactosidase (SA- -gal) staining. The occurrence of positive cells (about 89% in 133p53i-1- and 80% in 133p53i-2-transfected cells) at 5 dpi was significantly increased by 133p53 knockdown upon -irradiation, compared to that in the irradiated siNS control (about 40%; Figure 5C, 5D and Supplementary information, Figure S17). Taken together, loss of function of 133p53 increased DNA DSBs upon -irradiation, which in turn inhibited cell proliferation by arresting cell cycle at the G2 phase, fnally resulting in cell senescence.


# 133p53 does not form a complex with either RAD51 or RPA

It was proposed that the p53 protein directly interacts with either RAD51 [18] or RPA [19] to inhibit DNA DSB repair complex formation. Previous studies have shown that the DNA-binding core domain (94-312) of p53 is required for p53-RAD51 interactions, and its N-terminal domain (37-57) is required for p53-RPA interactions [36, 37], which suggests that 133p53 may not be able to form a complex with these two proteins. We performed a co-immunoprecipitation (co-IP) experiment to test this hypothesis by co-transfecting HA-RAD51 or HA-RPA2 with p53, 133p53 or both, into H1299 cells. The results showed that full-length p53 (Figure 6A, lanes 2 and 10), but not 133p53 (Figure 6A, lanes 3 and 11) formed a complex with either HA-RAD51 or HA-RPA2. It was observed that the protein level of RAD51, RPA2 133p53 was dramatically decreased when it was co-expressed with full-length p53 in the experiments, but the reason is currently not known.

# 113p53/ 133p53 upregulates the expression of key DNA DSB repair genes

We investigated the molecular mechanisms by which 113p53/133p53 promotes DNA DSB repair independent of p53. We co-injected a linearized plasmid (to mimic DNA DSB stress) with either *p53*, *113p53* or *p53*-plus-*113p53* mRNA into *p53*<sup>M214K</sup> mutant embryos and analyzed the expression of DSB- and p53-response genes by quantitative reverse transcription PCR (qRT-PCR). Unlike two p53-responsive genes, *p21* (a cell cycle inhibitor) and *mdm2* (an E3 ligase), the expression





of 8 out of 14 DNA DSB repair genes (including *lig4*, *rad54*, *recq4*, *wrn*, *rad51*, *rad52*, *mre11* and *xrcc4*) was signif cantly downregulated by p53. 113p53 suppressed the inhibitory effect of p53 on the expression of all of these genes except for *wrn* (Figure 6B), which may explain 133p53's ability to neutralize the inhibitory effect of full-length p53 on DSB repair.

Strikingly, 113p53 alone promoted the expression of *rad51* (required for HR repair [38]), *lig4* (required for NHEJ repair [39]), and *rad52* (required for SSA repair [40]) (Figure 6B). We examined the transcriptional activity of human 133p53 by transfecting QSG7701 cells with siNS, p53i, 133p53i-1 or 133p53i-2 and then treating them with -irradiation. The results from both qRT-PCR and protein analyses showed that the expression levels of RAD51, LIG4 and RAD52 were all upregulated at 12 hpi (Figure 6C; Supplementary information, Figure S18). The upregulation of these genes after -irradiation was attenuated by knockdown of 133p53 and enhanced by knockdown of p53 (Figure 6C; Supplementary information, Figure S18).

We generated two 113p53 mutants to test whether the function of 113p53 in facilitating DNA DSB repair is dependent on its transcriptional activity,  $113p53^{R143H}$ and  $113p53^{R250W}$  (the number denotes the mutation's position in the full-length zebrafish p53).  $113p53^{R143H}$ and  $113p53^{R250W}$  correspond to the R175H and R282W mutations in full-length human p53, respectively, which are known to lose their DNA binding capacity [41]. qRT-PCR results showed that, unlike WT 113p53, the two

113p53 mutants did not upregulate the expression of *rad51*, *lig4* and *rad52* (Figure 6D). Further experiments demonstrated that the two mutants also failed to promote HR, NHEJ and SSA repairs (Figure 6E).

Next, we used zebrafsh  $p53^{M214K}$  mutant embryos to investigate the roles of *rad51*, *lig4* and *rad52* in the DNA DSB repair pathways, in the context of 113p53. Specific MOs were used to knock down *rad51*, *lig4* or *rad52* under different conditions in embryos overexpressing

113p53 and an HR, NHEJ or SSA reporter construct. Our results revealed that knockdown of *rad51*, *lig4* and *rad52* significantly attenuated the effect of 113p53 on promoting DNA DSB repair in the corresponding pathway (Figure 6F). All of these data suggested that 113p53's transcriptional activity is important for DNA DSB repair.


(A)

113p53 binds to a novel p53 RE in the promoters of rad51, lig4 and rad52

A previous study showed that human p53 repressed *RAD51* transcription by directly binding to its promoter [20]. We tested whether 113p53 also has a direct role in *rad51* transcription by cloning the zebrafsh *rad51* promoter of 5 kb upstream of the *rad51* transcriptional start site and generating the *rad51p:Egfp* reporter construct (Figure 7A). This 5-kb fragment recapitulates the pattern of endogenous *rad51* expression in response to p53 and

113p53 expression (Figure 7B). Two putative p53 REs were found within the promoter region of rad51 at positions 3 384 and 1 165 nucleotide (Figure 7A). Interestingly, the arrangements of four pentamers found in both of the REs are novel compared to those reported previously (Figure 7A). We found that the deletion of RE1 switched the effect of p53 from repressing to promoting Egfp expression. The deletion of RE2 abrogated the effect of 113p53 but enhanced the suppressing effect of p53 (Figure 7B). A gel retardation experiment revealed that both p53 and 113p53 could bind to RE2, whereas only p53 could bind to RE1 (Figure 7C). These results suggest that p53 first binds to RE1 to suppress rad51 expression. In the absence of RE1, p53 binds to RE2 to promote rad51 expression, and RE2 serves as the sole site for 113p53 binding to promote rad51 expression.

Further analysis showed that the p53-repressing RE (RE1) and 113p53-activating RE (RE2) were also present in zebrafish *rad52* and *lig4* promoters (Figure 7D) and in human *RAD51*, *LIG4* and *RAD52* promoters (Supplementary information, Figure S19). A chromatin immunoprecipitation (ChIP) assay was performed to study whether p53 and 113p53 bind to their respective REs in the promoters of three DNA DSB repair genes *in vivo* upon -irradiation. As shown in Figure 1B, expression



(C) B (D)

of full-length p53 reached its peak level at 4 hpi, while 113p53 expression peaked at 24 hpi. Based on this, we used untreated embryos as the controls and sampled irradiated embryos at 4 and 24 hpi. We used the A7-C10 zebrafish p53 monoclonal antibody, recognizing both p53 and 113p53, to perform ChIP experiment. First, we validated our ChIP products by analyzing the occupancy of p53 on the two known p53 REs in the promoter of 113p53 by qPCR. The enrichment of both p53 RE1 and RE3 of the 113p53 promoter in the ChIP products was nicely correlated with the dynamic expression levels of p53 at 4 and 24 hpi (Supplementary information, Figure S18A). Next, we examined the occupancy of p53 and 113p53 in the promoters of *rad51*, *rad52* and *lig4*. The qPCR analysis showed that RE1 sequences (p53-repressing RE) of rad51, rad52 and lig4 were all enriched in the ChIP products from the 4-hpi samples (Figure 7E). As the expression level of p53 peaked at 4 hpi (Figure 1B), this result suggests that occupancy of RE1 in these promoters by p53 at this stage locks the expression of these genes at a repressive status. In contrast, RE2 sequences (113p53-activating RE) of rad51, rad52 and lig4 were all enriched in the ChIP products from the 24hpi samples (Figure 7E). As the level of 113p53 greatly exceeds that of p53 at 24 hpi (Figure 1B), these results demonstrate that the promoters of the three genes are switched from a status of repression by p53 at RE1 to a status of activation by 113p53 at RE2 in vivo. This occurs as a consequence of the dynamic change of expres-

sion levels of p53 and 113p53, from 4 to 24 hpi. To analyze whether the binding of 113p53 to RE2 of these three DNA DSB repair gene promoters is independent of full-length p53, we overexpressed HA-p53 and HA- 113p53 in  $p53^{-/-}$  mutants. An HA monoclonal antibody was used to perform the ChIP assay. The assay demonstrated that RE1 was enriched in the ChIP products from the sample overexpressing HA-p53, whereas the sample overexpressing HA- 113p53 showed enrichment at RE2 in the promoters of zebrafish lig4, rad52 and rad51 (Supplementary information, Figure S20), further confirming the ChIP assay results performed with irradiated zebrafsh embryos. These results demonstrate that 113p53 upregulates the expression of rad51, lig4 and rad52 by binding to a novel type of p53 REs in their promoters.


## Discussion

(B)


Up to 13 human p53 isoforms have been identified, and these isoforms are generated through alternative initiation of translation, use of an internal promoter or alternative splicing [42]. p53 isoforms can modulate p53 functions either synergistically or antagonistically, depending on the isoform's structure and the target genes affected [42]. However, how these isoforms affect DNA damage repair is rarely studied. Many studies have demonstrated that full-length p53 inhibits DNA DSB repair [12-14]. A recent study using human cells has shown that, in response to -irradiation treatment, p53 pulses induce apoptosis at the early stage and postpone DNA DSB repair to the later stage [22]. Here, we found that the p53 isoform 113p53/ 133p53 is strongly induced by -irradiation, but not by UV irradiation and heat shock treatment. Interestingly, we observed that, upon -irradiation, the levels of full-length p53 and 113p53p53 proteins in the treated zebrafsh embryos were differentially expressed. Full-length p53 protein level peaked early, at 4 hpi, whereas 113p53p53 protein level peaked later, at 24 hpi. We showed previously that 113p53/ 133p53 is a p53 target gene and inhibits p53-mediated apoptosis by modulating the expression of p53 target genes [26]. All of our fndings imply that 113p53/ 133p53 may coordinate with full-length p53 to regulate cell death and DNA DSB repair in response to DNA DSB stress. Through Egfp-repairing-aided visual-plus-quantitative analysis reporter systems, comet assay and repair foci analysis, we demonstrated that 113p53/ 133p53 promotes all three DNA DSB repair pathways in both zebrafsh and human cells in a p53-independent manner. Further experiments with -irradiated zebrafish embryos showed that the proportion of apoptotic cells peaked around 8 hpi and dropped to the basal level at 24 hpi, which correlated well with the level of full-length p53 protein. In contrast, the extent of DNA damage decreased rapidly after 28 hpi, corresponding to the level of 113p53 protein. We revealed how changes in the levels of p53 and 113p53 proteins regulate cell death and DNA DSB repair in response to DNA damage. To minimize DNA DSBs as the frst defense at the early stage of DNA damage response, full-length p53 is induced to a high level to guide cells

(A)

С



t



with severe DNA damage to undergo apoptosis. The subsequent expression of 113p53, as the second wave of defense, inhibits apoptosis in the remaining cells with repairable DNA damage and, at the same time, promotes DNA DSB repair. Our findings demonstrate that

113p53/ 133p53 is a pro-survival factor and may also imply possible roles of the other p53 isoforms in different DNA damage repair pathways.

The importance of 113p53/ 133p53 for cell survival and its signifcance to the survival of a whole organism is further demonstrated in the  $113p53^{M/M}$  mutant. Although the  $113p53^{MM}$  mutant zebraf sh grows normally in standard growth conditions, it is sensitive to -irradiation. No mutant embryos were able to survive longer than 5 days after irradiation, while irradiated WT embryos exhibited a survival rate of about 30%. Sensitization to -irradiation is due to an increase in both apoptotic activity and the extent of DNA damage in the  $113p53^{M/M}$  mutant embryos upon irradiation. The fact that the mortality of irradiated 113p53<sup>M/M</sup> mutant embryos was much higher than that of irradiated WT embryos, even when apoptosis was inhibited by bcl2 mRNA injection, strongly suggests that in addition to its anti-apoptosis activity, the function of promoting DSB damage repair of 113p53 is crucial in protecting an organism from DNA damage. Similarly, in human cells the ratios of cells at the G2 phase and SA--gal-positive cells were signifcantly higher in irradiated

133p53-knockdown cells, which eventually resulted in smaller colony sizes and fewer colonies. A previous study reported that the basal expression of 133p53 inhibits p53-mediated replicative senescence through downregulating the expression of  $p21^{WAF1}$  and miR-34a in normal human fibroblasts [29]. 133p53 knockdown-induced senescence was accompanied by the attenuation of BrdU (bromo-deoxyuridine) incorporation, which suggests that the cell senescence was due to cell cycle arrest at the G1 phase [29]. In this study, we showed that knockdown of 133p53 in cells exposed to DNA DSB stress also resulted in cell senescence. However, this senescence was caused by unrepaired DNA DSBs and accompanied by the increase of cells at the G2 phase. These results suggest that 133p53 regulates cell replicative senescence in the normal condition and cell senescence upon a DNA damage stress by different mechanisms.


One important rationale for p53 inhibition of DNA DSB repair is its direct interactions with repair proteins, such as RAD51 and RPA, to prevent repair complex formation. The key residues in human p53's DNA binding core domain (including residues 102, 103, 105, 114, 115, 122 and 126) are required for interactions with RAD51, and those in the N-terminal motif (residues 37-57) are required for interactions with RPA. These key amino acid residues are absent in the 133p53 protein [36, 37]. This might be the reason that 133p53 was not co-immunoprecipitated with RAD51 and RPA in this study. However, 133p53 may interrupt the interaction between p53 and HA-Rad51 or HA-RPA2, which was probably due 133p53's ability to form a hetero-complex with p53 to [28, 43], which may allow it to neutralize the DSB repair inhibitory effect of full-length p53.

113p53/ 133p53 is an N-terminally truncated protein without the transactivation domain. Our previous studies showed that, although co-expression of 113p53 and p53 alters the expression patterns of p53 downstream genes such as p21, mdm2 and bcl2L, expressing 113p53 alone results in little transcriptional activity on these genes in the  $p53^{M214K}$  mutant background [26]. Surprisingly, here we found that 113p53 upregulates the expression of the DNA DSB repair genes rad51, lig4 and rad52, independent of full-length p53. The transcriptional activity of

113p53 is required for its positive effect on DNA DSB repair as, apart from impairing its transcriptional activity, mutations in its DNA-binding domain also abolished its ability to promote DNA DSB repair. Through promoter

3	6	5

Α			
	MADER BARRAN	 70 ka	ביאמונה איניייייייייייייייייייייייייייייייייי



functional analysis, gel shift and ChIP assays, we demonstrated that 113p53 binds to a novel type of p53 RE in the promoters of zebrafsh *rad51*, *lig4* and *rad52* genes. A similar type of RE was also found in the promoter regions of human *RAD51*, *LIG4* and *RAD52*. It is currently unclear how 113p53/ 133p53 lacking the transactivation domain of full-length p53 exerts a transcriptional activity independent of full-length p53. A recent study showed that p53 isoforms, including 133p53, differentially regulate p73 transcriptional activities by protein interactions [44], which suggests that 113p53/ 133p53 may interact with p73 or its isoforms to achieve its transcriptional activity.

From an evolutionary point of view, given a DNA damage stress condition, the first, crucial action taken by an organism is to survive under such environment. The second action is to minimize genetic insults to avoid genetic diseases during the course of development and reproduction. Here, we demonstrate that the

113p53/ 133p53 is a pro-survival factor for DNA damage stress, and induction of its expression prevents apoptosis and promotes DNA DSB repair, thus inhibiting cell senescence. However, whether 113p53/ 133p53 also plays a role in preventing diseases in response to DNA damage needs to be further explored. It would be very interesting to know whether the *113p53<sup>MM</sup>* mutant exhibits a shortened life-span and high frequency of tumorigenesis in response to low dosage of -irradiation.

About 60% of all cancer patients are treated with radio-therapy alone or in combination with other anticancer treatments, including surgery [45, 46]. Most patients can tolerate radiation treatment well, with 5%-10% suffering severe side effects in normal tissue. This radio-sensitivity is partly genetically determined. A few molecular markers have been successfully applied to predict the radio-sensitivity in individual patients [47]. Here, we demonstrate that 133p53 is strongly induced by ionizing radiation and protects cells from death and senescence through preventing apoptosis and promoting DNA DSB repair, which suggests that the induction of

*133p53* expression in normal cells and tissues provides a potential marker to assess a patient's tolerance to radiation treatment.

## **Materials and Methods**

#### Zebrafsh husbandry

Zebrafsh was raised and maintained in standard zebrafsh units at Zhejiang University. The  $p53^{-/-}$  mutant allele  $p53^{M214K}$  line [32] was provided by professor Thomas Look at Harvard Medical School (Boston, USA).

#### Cell culture

H1299 (TCHu160) and QSG-7701 (GNHu7) cells were purchased from the cell bank of the Chinese Academy of Sciences (Shanghai, China). HR-U2OS [33] was a gift from professor Huang Jun at Zhejiang University (Hangzhou, China). Plasmids and siRNAs were transfected into cells with FuGENE HD (Roche) and Lipofectamine 2000 transfection reagents, respectively.

#### HR, NHEJ and SSA assays

The construction of the HR, SSA and NHEJ visual-plus-quantitative assay systems and analyzing procedures were performed as described previously [31] (Supplementary information, Figure S2). The primers used in qPCR are listed in Supplementary information, Table S1.

The H1299 cell line was used for HR, SSA, and NHEJ assays in human cells. 1.5  $\mu$ g of I-SceI-cut HR, 0.5  $\mu$ g of I-SceI-cut

NHEJ or 0.5  $\mu$ g of I-SceI-cut SSA plasmid DNA was co-transfected with 0.5  $\mu$ g of CMV-p53, 1.5  $\mu$ g of CMV- 133p53 or 0.5  $\mu$ g of CMV-p53 with 1.5  $\mu$ g of CMV- 133p53 into 1  $\times$  10<sup>6</sup> H1299 cells. An uncut plasmid was transfected as the negative control. Transfected cells were cultivated for 24 h at 37 °C and subsequently subjected to FACS analysis with a FACS Calibur Flow Cytometer (BD Biosciences). A minimum of 10 000 cells per sample were analyzed. DNA was also extracted at 24 hpt for qPCR analysis, as described above.

### -irradiation, UV-irradiation and heat shock treatments

Zebrafsh embryos at 24 hpf were irradiated with a dose of 16 gray of -ray from a <sup>137</sup>Cs source. For UV-irradiation treatment, embryos at 24 hpf were treated with a total energy of 75 mJ/cm<sup>2</sup> UV irradiation by a UV source (UV-CL-1000 Ultraviolet Crosslinker) emitting 254 nm light (UVP, USA). For heat shock treatment, 24-hpf embryos, growing at 28.5 °C, were transferred to a 38 °C growth chamber until protein extraction.

For -irradiation in human cell lines, untreated or transfected cells at 24 hpt were irradiated with a dose of 10 gray of -ray. For UV-irradiation treatment, cells were treated with a total energy of  $30 \text{ mJ/cm}^2$  UV. For heat shock treatment, cells cultured at 37 °C were transferred to a 42 °C growth chamber for 8 h and then returned to 37 °C until protein extraction.

#### Comet assay

For the comet assay in zebrafsh, ~100 irradiated or un-irradiated control embryos were sampled at 28 and 36 hpi, and subjected to cell dissociation in ice-cold PBS containing 20 mM EDTA (without  $Mg^{2+}$  and  $Ca^{2+}$ ). The comet assay was performed with a OxiSelectTM comet assay kit (3-well slides, Cell Biolabs Inc.) according to the manufacturer's recommendations. Embedded cells were treated with a lysis buffer at pH 7 without alkaline treatment to release the double-stranded DNA. For data processing, each comet picture was measured with the software ImageJ 1.45 (National Institutes of Health) [48] and the extent of damage in individual cells was calculated as described in Supplementary information, Figure S6.

For the comet assay in the human cell line, QSG7701 cells were transfected with siRNAs, followed by -irradiation, as described in the apoptosis and cell cycle assay. The irradiated cells were fxed in 70% ethanol at 48 hpi and subjected to the comet assay, as described in the zebrafsh comet assay.

#### Construction of overexpression plasmids

Zebrafsh *p53*, *113p53* and *bcl2L* and human *CMV-p53* and *CMV- 113p53* were constructed as described previously [49]. Human *CMV-HA-RAD51* was amplifed using the primer pair *HA-HuRad51-BamHI*-For and *HA-HuRad51-XbaI*-Rev. Human *CMV-HA-RPA2* was amplifed using the primer pair *HA-HuRPA2*-For-*BamHI* and *HA-HuRPA2*-Rev-*EcoRI*. The primer sequences are provided in Supplementary information, Table S1.

# Generation of zebrafsh $113p53^{MM}$ mutant with the TALEN technique

The *113p53* promoter is located in the fourth intron of the full-length *p53* gene [24, 26]. The third p53 RE in the *113p53* promoter (5'-cagtggaggttGAACATGTCTGAACTTGTCCtgatt-gagcagtggggg-3'; the sequence of p53 RE is shown in upper case) was chosen for the TALEN targeting site [50]. We placed the third

p53 RE at the spacer region where indels often occur. The two TALEN plasmids with the target binding sites (shown in red letters in Figure 2A) were ordered from ViewSolid Biotech. The two TALEN mRNAs were prepared and co-injected into WT embryos at one-cell stage according to the manufacturer's recommendations.

The TALEN-injected embryos were raised to adulthood and outcrossed with WT fsh. The F1 embryos were used to identify mutant founders. The tail of F1 adult fish was used to identify heterozygous mutants. To identify the genetic mutants, a pair of primers (5'-GGCAGTCTAGCTTATGTGT-3' and 5'-GCTT-GACTGTCCAGCACTA-3') flanking the target site, were used to amplify a 400-bp DNA fragment from genomic DNA. The PCR product contains a digestion site of the restriction enzyme Hpy188III around the third p53 RE. The PCR fragment from WT can be digested into two 200-bp bands, while the PCR fragment from a mutant remains as a 400-bp band. The fragment deletions were subsequently confrmed by sequencing.

### SA- -gal staining

For SA- -gal staining, QSG7701 cells were transfected with siRNAs followed by -irradiation, as described in the apoptosis and cell cycle assays. At 48 hpi, the irradiated cells were fxed in 4% PFA and subjected to SA- -gal staining with Cell Senescence SA- -Gal Staining Kit (Beyotime, C0602). Statistics was obtained from three repeat experiments.

#### rad51 promoter reporter assay

A 5.0-kb DNA fragment upstream of the transcriptional start site of *rad51* (Figure 7A) was amplifed from genomic DNA (AB strain WT zebrafsh) with the primer pair *rad51*pro-*XhoI*-For and *rad51*pro-*BamHI*-Rev, and cloned into the pEgfp-1 vector to generate the plasmid *rad51p:Egfp*. The single motif deletion promoters *rad51p-RE1:Egfp* or *rad51p-RE2:Egfp* (Figure 7B) were amplifed from the *rad51p:Egfp* plasmid using their respective primer pairs. The primers sequences used are listed in Supplementary information, Table S1. The promoter *rad51p- RE1&2:Egfp*, with a double-deletion, was generated from the single deletion plasmid.

#### RNA analysis

For northern blot hybridization, full-length *Egfp* and 21-760bp DNA fragment of *rad51* cDNA were labeled with Digoxigenin (DIG) to form probes. qRT-PCR in zebrafish was performed as described previously [26]. The primer sequences and accession numbers of the analyzed genes are listed in Supplementary information, Table S1.

#### Electrophoretic mobility shift assay (EMSA)

Twenty-six-bp DNA fragments of RE1 and an RE1 mutant with 6 bp mutated, and 39 bp of RE2 and an RE2 mutant with 6 bp mutated of the *rad51* promoter (Figure 7C) were artificially synthesized and labeled with biotin as probes (Shanghai Sangon). Nuclear proteins were extracted from injected embryos at 8 hpf with a nuclear protein and cytoplasm protein extraction kit (Beyotime, P0027). Forty fmol of labeled probe was incubated with 2 µg of extracted nuclear protein for 20 min. To specifcally block band shift, 8 pmol of unlabeled probe or 200 ng of A7-C10 zebraf sh p53 monoclonal antibody was analyzed with a light shift chemiluminescent EMSA kit (Pierce, 20148), according to the manufac-

### turer's instructions.

## ChIP assay

ChIP assays were performed as described previously [26]. For immunoprecipitation of endogenous p53 and 113p53, WT embryos were treated with 16 gray of -ray. Untreated embryos, and irradiated embryos at 4 and 24 hpi were sampled. Chromatin was sheared into 200-800-bp fragments with Cole-Parmer sonicator equipped with a 2-mm tip. The A7-C10 zebrafsh p53 antibody was used to perform immunoprecipitation with the sonicated DNA-protein complex solutions, while IgG was used as the non-specifc binding control with the same amount of the sonicated solution. Primers used in qPCR are listed in Supplementary information, Table S1. Total pulled down DNA was normalized with a pair of non-specifc primers for the -actin exon. The specifc primers for p53 RE1 and RE3 of the *113p53* promoter were used as a p53-binding positive control [26].

To immunoprecipitate ectopically expressed HA-p53 and HA-

113p53, ~40 pg of pGEMT plasmid was injected alone, or co-injected with 50 pg of *HA-p53* mRNA and 300 pg of *HA- 113p53* mRNA, into one-cell-stage embryos. At 7 hpf, injected embryos from each treatment were sampled. HA antibody matrix (Abmart) was used for immunoprecipitation. Total DNA was normalized with exon-specific primers. Meanwhile, p53, RE1, and RE3 of *113p53* promoter were used as p53-binding positive control.

### Western blot, co-IP and immunof uorescence staining

Western blotting was performed as described previously [49]. Zebrafish p53 monoclonal antibody (A7-C10) was generated as described [49].

For co-IP ar	nalysis, tran	nsfected cell	s were cu	ultivated for 24	h					
at 37 °s		p53		wes %sed	_ b	des cd a A7RE	N1,qnd			(
a om	с	r	v	_ e	sr e <sup>a</sup>	btsqs	bm b	с	а	с
gere ì la l	eda	an								

r

recombination. Cancer Res 2003; 63:2596-2605.

- 17 Boehden GS, Akyuz N, Roemer K, Wiesmuller L. p53 mutated in the transactivation domain retains regulatory functions in homology-directed double-strand break repair. *Oncogene* 2003; :4111-4117.
- 18 Buchhop S, Gibson MK, Wang XW, et al. Interaction of p53 with the human Rad51 protein. Nucleic Acids Res 1997; :3868-3874.
- 19 Romanova LY, Willers H, Blagosklonny MV, Powell SN. The interaction of p53 with replication protein A mediates suppression of homologous recombination. *Oncogene* 2004; :9025-9033.
- 20 Arias-Lopez C, Lazaro-Trueba I, Kerr P, *et al.* p53 modulates homologous recombination by transcriptional regulation of the *RAD51* gene. *EMBO Rep* 2006; :219-224.
- 21 Purvis JE, Karhohs KW, Mock C, *et al.* p53 dynamics control cell fate. *Science* 2012; **336**:1440-1444.
- 22 Zhang XP, Liu F, Cheng Z, Wang W. Cell fate decision mediated by p53 pulses. *Proc Natl Acad Sci USA* 2009; :12245-12250.
- 23 Bourdon JC, Fernandes K, Murray-Zmijewski F, et al. p53 isoforms can regulate p53 transcriptional activity. *Genes Dev* 2005; :2122-2137.
- 24 Chen J, Ruan H, Ng SM, *et al.* Loss of function of def selectively upregulates {Delta}113p53 expression to arrest expansion growth of digestive organs in zebrafsh. *Genes Dev* 2005; :2900-2911.
- 25 Chen J, Peng J. p53 isoform delta113p53 in zebrafsh. Zebrafish 2009; 6:389-395.
- 26 Chen J, Ng SM, Chang C, et al. p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafsh. *Genes Dev* 2009; :278-290.
- 27 Marcel V, Vijayakumar V, Fernandez-Cuesta L, *et al.* p53 regulates the transcription of its Delta133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. *Oncogene* 2010; :2691-2700.
- 28 Aoubala M, Murray-Zmijewski F, Khoury MP, et al. p53 directly transactivates Delta133p53alpha, regulating cell fate outcome in response to DNA damage. Cell Death Differ 2011; :248-258.
- 29 Fujita K, Mondal AM, Horikawa I, et al. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 2009; :1135-1142.
- 30 Bernard H, Garmy-Susini B, Ainaoui N, *et al.* The p53 isoform, delta133p53alpha, stimulates angiogenesis and tumour progression. *Oncogene* 2013; :2150-2160.
- 31 Liu J, Gong L, Chang C, *et al.* Development of novel visual-plus quantitative analysis systems for studying DNA double-strand break repairs in # b